Aquatic Capital Management LLC Purchases New Shares in Anika Therapeutics, Inc. (NASDAQ:ANIK)

Aquatic Capital Management LLC acquired a new position in shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 2,578 shares of the biotechnology company’s stock, valued at approximately $42,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Los Angeles Capital Management LLC lifted its position in shares of Anika Therapeutics by 9.1% during the fourth quarter. Los Angeles Capital Management LLC now owns 11,700 shares of the biotechnology company’s stock worth $193,000 after purchasing an additional 980 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Anika Therapeutics by 3.7% during the 4th quarter. Wellington Management Group LLP now owns 39,785 shares of the biotechnology company’s stock worth $655,000 after buying an additional 1,407 shares in the last quarter. R Squared Ltd acquired a new position in Anika Therapeutics during the 4th quarter worth $27,000. Wells Fargo & Company MN boosted its position in Anika Therapeutics by 31.1% in the 4th quarter. Wells Fargo & Company MN now owns 7,421 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 1,759 shares during the last quarter. Finally, Barclays PLC increased its stake in shares of Anika Therapeutics by 6.4% in the 4th quarter. Barclays PLC now owns 34,757 shares of the biotechnology company’s stock valued at $571,000 after buying an additional 2,093 shares during the period. Institutional investors and hedge funds own 91.53% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ANIK shares. Barrington Research cut their price target on Anika Therapeutics from $25.00 to $20.00 and set an “outperform” rating on the stock in a research note on Thursday, March 13th. StockNews.com raised shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. Finally, B. Riley began coverage on shares of Anika Therapeutics in a research note on Thursday, April 17th. They set a “buy” rating and a $21.00 price target for the company.

Anika Therapeutics Trading Down 2.7 %

NASDAQ ANIK opened at $14.10 on Wednesday. Anika Therapeutics, Inc. has a 12 month low of $12.83 and a 12 month high of $29.12. The stock has a 50-day simple moving average of $15.01 and a 200 day simple moving average of $16.71. The company has a market capitalization of $202.14 million, a PE ratio of -2.12 and a beta of 0.76.

Anika Therapeutics (NASDAQ:ANIK) last announced its quarterly earnings results on Wednesday, March 12th. The biotechnology company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.13). Anika Therapeutics had a negative net margin of 59.40% and a negative return on equity of 2.22%. The company had revenue of $30.60 million during the quarter, compared to the consensus estimate of $29.00 million. As a group, sell-side analysts predict that Anika Therapeutics, Inc. will post -0.84 earnings per share for the current fiscal year.

Anika Therapeutics Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.